MX344450B - Proceso para la preparacion de derivados de imidazo[2,1-b][1,3]ben zotiazol. - Google Patents

Proceso para la preparacion de derivados de imidazo[2,1-b][1,3]ben zotiazol.

Info

Publication number
MX344450B
MX344450B MX2012005235A MX2012005235A MX344450B MX 344450 B MX344450 B MX 344450B MX 2012005235 A MX2012005235 A MX 2012005235A MX 2012005235 A MX2012005235 A MX 2012005235A MX 344450 B MX344450 B MX 344450B
Authority
MX
Mexico
Prior art keywords
imidazo
preparation
isoxazol
morpholin
ethoxy
Prior art date
Application number
MX2012005235A
Other languages
English (en)
Other versions
MX2012005235A (es
Inventor
Rathan Prasad Achampeta
david gross Timothy
Rao Citineni Janakiram
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of MX2012005235A publication Critical patent/MX2012005235A/es
Publication of MX344450B publication Critical patent/MX344450B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se provee un proceso para la preparación de N-(5-ter-butil-isoxazol-3-il)-N'-{4-[7-(2-morfolin-4 -il-etoxí)imidazo-[2,1-b][1,3]benzotiazol-2-il]feni}urea, o una sal, solvato, hidrato o polimorfo farmacéuticamente aceptable de la misma. N-(5-ter-butil-isoxazol-3-iI)-N'-{4-[7-(2-morfoIin-4-iI- etoxi)midazo-[2,1-b][1,3]-benzotiazol-2-il]fenil}urea es útil para tratar, prevenir y/o administrar enfermedades ocondiciones, incluyendo pero sin limitación a, enfermedades proliferantes, enfermedades mediadas con FLT-3, y cánceres. N-(5-ter-butil-isoxaz ol-3-il)-N'-{4-[7-(2-morfoIin-4-il-etoxi)-imidazo-[2,1-b][1,3]ben zótiazol-2-iI]fenil}urea es representado por la estructura mencionada.
MX2012005235A 2009-11-05 2010-11-04 Proceso para la preparacion de derivados de imidazo[2,1-b][1,3]ben zotiazol. MX344450B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25855009P 2009-11-05 2009-11-05
PCT/US2010/055399 WO2011056939A1 (en) 2009-11-05 2010-11-04 Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives

Publications (2)

Publication Number Publication Date
MX2012005235A MX2012005235A (es) 2012-06-19
MX344450B true MX344450B (es) 2016-12-16

Family

ID=43333187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005235A MX344450B (es) 2009-11-05 2010-11-04 Proceso para la preparacion de derivados de imidazo[2,1-b][1,3]ben zotiazol.

Country Status (10)

Country Link
US (1) US9284332B2 (es)
EP (2) EP3150612A1 (es)
JP (2) JP5762426B2 (es)
KR (1) KR101819245B1 (es)
CN (2) CN104447801A (es)
CA (1) CA2778940C (es)
ES (1) ES2605621T3 (es)
HU (1) HUE029771T2 (es)
MX (1) MX344450B (es)
WO (1) WO2011056939A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
SI2429524T1 (sl) 2009-05-14 2020-07-31 Ambit Biosciences Corporation S pršenjem sušena formulacija AC220
CN104513259B (zh) * 2013-09-26 2017-06-16 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
IT201900015030A1 (it) 2019-08-26 2021-02-26 Univ Degli Studi Di Palermo Nuovi agenti terapeutici per il trattamento di patologie ematologiche

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025A (en) * 1850-01-15 Buckle
WO1998006724A1 (fr) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique
JPH11189596A (ja) * 1997-12-25 1999-07-13 Yamanouchi Pharmaceut Co Ltd メタボトロピックグルタメート受容体作用薬及び新規イミダゾベンゾチアゾール誘導体
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
KR101549364B1 (ko) * 2006-03-17 2015-09-01 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
EP2023919A4 (en) * 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
KR20150104231A (ko) 2007-09-19 2015-09-14 암비트 바이오사이언시즈 코포레이션 Ｎ-(5-ｔｅｒｔ-부틸-이속사졸-3-일)-Ｎ''-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-Ｂ][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도
EP2596795A1 (en) 2007-11-08 2013-05-29 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
HUE032873T2 (en) * 2008-03-17 2017-11-28 Ambit Biosciences Corp 1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
JP5686736B2 (ja) * 2008-11-06 2015-03-18 アムビト ビオスシエンセス コルポラチオン プロテインキナーゼモジュレーターとしてのイミダゾロチアゾール化合物

Also Published As

Publication number Publication date
ES2605621T3 (es) 2017-03-15
CN102639539A (zh) 2012-08-15
EP2496584A1 (en) 2012-09-12
US9284332B2 (en) 2016-03-15
US20130005966A1 (en) 2013-01-03
MX2012005235A (es) 2012-06-19
KR20120081622A (ko) 2012-07-19
JP2013510162A (ja) 2013-03-21
JP2015212272A (ja) 2015-11-26
HUE029771T2 (en) 2017-04-28
JP5762426B2 (ja) 2015-08-12
CA2778940C (en) 2018-10-16
EP2496584B1 (en) 2016-09-21
KR101819245B1 (ko) 2018-01-16
CN102639539B (zh) 2014-12-10
CA2778940A1 (en) 2011-05-12
CN104447801A (zh) 2015-03-25
EP3150612A1 (en) 2017-04-05
WO2011056939A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
EA201071370A1 (ru) Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
UA110467C2 (uk) Похідні оксазину
NZ596739A (en) Methods of treating proliferative diseases
MX2011012264A (es) Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2).
NZ591425A (en) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
PH12015501878A1 (en) Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
NZ604708A (en) Macrocyclic compounds as trk kinase inhibitors
TW200732336A (en) Alyphactic heterocyclic compounds
UA109800C2 (xx) ПОХІДНІ 6,7-ДИГІДРОПІРАЗОЛО$1,5-a]ПІРАЗИН-4-ІЛАМІНУ, КОРИСНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
NO20044974L (no) Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
NO20084997L (no) Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
MX2010002396A (es) Metodos para administrar n-(5-ter-butil-isoxazol-3-il)-n?-{4-[7-(2 -morfolin-4-il-etoxi)imidazo[2, 1-b][1,3]benzotiazol-2-il] fenil} urea para tratar enfermedaes proliferativas.
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
MX2013000362A (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
MX344450B (es) Proceso para la preparacion de derivados de imidazo[2,1-b][1,3]ben zotiazol.
TN2012000153A1 (en) Heterocyclic sulfonamide derivatives useful as mek inhibitors
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
MX2010002295A (es) Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
WO2008104847A3 (en) Processes for the preparation of pramipexole and salts thereof
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration